Sit is a structurally unique anticonvulsant that has been introduced as adjuvant therapy of Dravet syndrome, a rare form of severe childhood epilepsy. There is limited information on the safety of sit, but it has not been associated with serum aminotransferase elevations or linked to cases of clinically apparent liver injury. 
